Tempest Therapeutics(US:TPST)2025-11-05 14:04Financial Performance - Tempest ended Q3 2025 with $7.5 million in cash and cash equivalents, down from $30.3 million on December 31, 2024, primarily due to cash used in operating activities[5]. - The net loss for Q3 2025 was $3.5 million, or $0.79 per share, compared to a net loss of $10.6 million, or $5.32 per share, for the same period in 2024[5][15]. - For the nine months ended September 30, 2025, the net loss was $22.2 million, or $5.71 per share, compared to $28.0 million, or $15.48 per share, for the same period in 2024[10][15]. - Cash used in operating activities for the nine months ended September 30, 2025, was $23.2 million[10]. Expenses - Research and development expenses for Q3 2025 were $0.6 million, significantly lower than $7.6 million for Q3 2024, reflecting a $7.0 million decrease due to re-prioritization of strategic efforts[5][15]. - Year-to-date research and development expenses were $12.1 million, down from $17.7 million for the same period in 2024, a decrease of $5.6 million[10]. - General and administrative expenses remained stable at $3.0 million for Q3 2025, compared to $3.0 million for Q3 2024[6]. Assets and Liabilities - Total assets decreased to $17.1 million as of September 30, 2025, from $41.5 million on December 31, 2024[13]. - Total liabilities decreased to $10.8 million as of September 30, 2025, from $22.4 million on December 31, 2024[13]. Strategic Outlook - The company is pursuing strategic alternatives to maximize value for stockholders and is optimistic about the potential of its product candidates, including the upcoming TPST-1495 Phase 2 trial[2][11].